Chemed Corporation $CHE Shares Sold by TD Asset Management Inc

TD Asset Management Inc trimmed its holdings in shares of Chemed Corporation (NYSE:CHE) by 7.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 245,285 shares of the company’s stock after selling 19,586 shares during the period. TD Asset Management Inc’s holdings in Chemed were worth $119,437,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Alpine Bank Wealth Management acquired a new position in Chemed during the first quarter valued at approximately $29,000. HM Payson & Co. acquired a new position in Chemed during the first quarter valued at approximately $30,000. SVB Wealth LLC acquired a new position in Chemed during the first quarter valued at approximately $30,000. WPG Advisers LLC acquired a new position in Chemed during the first quarter valued at approximately $32,000. Finally, Geneos Wealth Management Inc. lifted its position in Chemed by 330.4% during the first quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock valued at $61,000 after buying an additional 76 shares in the last quarter. 95.85% of the stock is owned by institutional investors and hedge funds.

Chemed Trading Up 1.7%

Shares of NYSE:CHE opened at $437.00 on Wednesday. The company has a fifty day simple moving average of $448.72 and a 200 day simple moving average of $507.42. The firm has a market cap of $6.37 billion, a PE ratio of 22.47, a price-to-earnings-growth ratio of 2.50 and a beta of 0.43. Chemed Corporation has a 12-month low of $408.42 and a 12-month high of $623.60.

Chemed (NYSE:CHE) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $4.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.02 by ($1.75). The company had revenue of $618.80 million during the quarter, compared to the consensus estimate of $650.60 million. Chemed had a return on equity of 25.83% and a net margin of 11.56%.The firm’s quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter last year, the firm posted $5.47 EPS. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. As a group, equities research analysts forecast that Chemed Corporation will post 21.43 EPS for the current fiscal year.

Chemed Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, August 29th. Investors of record on Monday, August 11th were paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.5%. This is a boost from Chemed’s previous quarterly dividend of $0.50. The ex-dividend date was Monday, August 11th. Chemed’s payout ratio is presently 12.34%.

Insider Activity at Chemed

In related news, Director Patrick P. Grace sold 150 shares of Chemed stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $463.39, for a total value of $69,508.50. Following the completion of the sale, the director owned 3,397 shares in the company, valued at approximately $1,574,135.83. The trade was a 4.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director George J. Walsh III purchased 200 shares of the company’s stock in a transaction that occurred on Monday, August 4th. The stock was bought at an average price of $417.10 per share, with a total value of $83,420.00. Following the purchase, the director owned 3,523 shares of the company’s stock, valued at approximately $1,469,443.30. The trade was a 6.02% increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 13,162 shares of company stock worth $5,677,511 in the last ninety days. 3.29% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

CHE has been the topic of a number of recent research reports. Wall Street Zen cut shares of Chemed from a “buy” rating to a “hold” rating in a research report on Saturday, July 5th. Royal Bank Of Canada reduced their target price on shares of Chemed from $640.00 to $589.00 and set an “outperform” rating on the stock in a research report on Thursday, July 31st. Oppenheimer reduced their target price on shares of Chemed from $650.00 to $580.00 and set an “outperform” rating on the stock in a research report on Thursday, July 31st. Bank of America reduced their target price on shares of Chemed from $610.00 to $595.00 and set a “buy” rating on the stock in a research report on Wednesday, September 10th. Finally, Jefferies Financial Group raised shares of Chemed from a “hold” rating to a “buy” rating and boosted their target price for the stock from $490.00 to $550.00 in a research report on Tuesday, September 2nd. Four equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $578.50.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.